Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a $60 price target.
August 08, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Halozyme Therapeutics and maintained a $60 price target.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100